Innovent Biologics Announces Key Personnel ChangesDr. Hongyuan Sun (Stanley) officially announced via a professional social networking platform,He/She has joined Innovent Biologics as the Director of Business Development and Licensing.（Director of BD & Licensing）。According to public information, Dr. Sun Hongyuan possesses a triple background in scientific research, industrial investment, and business development. He earned his bachelor’s degree in Biotechnology from Fudan University and later obtained his Ph.D. in Cell Biology from the University of Chinese Academy of Sciences. His solid academic foundation provides support for the valuation of assets in the biological field.In the early stage of his career, he served as an Investment Manager at Xiantong Capital, focusing on equity investments in biopharmaceutical startups, where he accumulated experience in early-stage value assessment ranging from technology to commercialization.
In the industrial sector, Sun HongyuanAccumulated extensive experience in negotiation and implementation for domestic and international collaborative projects in the fields of cell therapy, biologics, and more:From 2019 to 2021, he was atWuXi BiologicsServed as Senior Manager of Business Development and Licensing, responsible for advancing out-licensing projects for biological drug products;From 2021 to 2023, he was atHarbour BioMedServed as Senior Manager and Associate Director of Business Development and Licensing, responsible for
Pipeline Asset Licensing and Corporate Strategic Partnership Development.In May 2023, he joined Legend Biotech as Associate Director of Business Development and Licensing, primarily responsible for the in-licensing and external collaborations of cell therapy pipeline assets. Leveraging his professional background in cell biology, he precisely aligned with sector demands and successfully facilitated the execution of multiple collaborative projects. Notably, Sun Hongyuan also holds the Chartered Financial Analyst (CFA) designation, a professional credential that enables him to balance scientific value with commercial prospects when evaluating innovative drug assets, thereby establishing a multidimensional assessment framework.Innovent, a leading domestic innovative pharmaceutical company, has expanded its product pipeline through business development (BD) collaborations in recent years.On May 29, Innovent announced that it had entered into a global strategic licensing and collaboration agreement with Pfizer,Focusing on 12 Breakthrough Projects in Early-Stage and Source Innovation for Oncology R&D, with a Total Transaction Value of Up to $10.5 Billion！According to industry statistics, InnoventThe total BD volume from 2025 to date has exceeded $31.85 billion, accounting for approximately 15% of the total value of overseas licensing deals for Chinese innovative drugs during the same period! This time, Sun HongThe joining of Yuan is expected to further strengthen Innovent’s business development capabilities.Source: PharmResearch Network
*This WeChat official account maintains a neutral stance toward all original and reposted content, statements, and viewpoints. The materials shared are intended solely for public benefit. If any reposted works or images contain incorrect authorship attributions or involve copyright infringement, please kindly notify the original authors and contact the editor for removal.
*Executive Editor| Muyi
*Reprint Permission |Xiao E 13166175613 (WeChat ID same as phone number))
*Business Cooperation | LiuTeacher13262726197(WeChat ID same as phone number)
